Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399757 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
A Phase 1 study of Prostate Cancer and Colorectal Cancer, sponsored by Apollo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT06399757 is a Phase 1 study of Prostate Cancer and Colorectal Cancer that is actively recruiting participants, run by Apollo Therapeutics. The registered enrollment target is 100 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT06399757, a Phase 1 study of Prostate Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Apollo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Conditions Studied
Interventions
- DRUG APL-5125
Study Locations (9)
California
- City of Hope - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
North Carolina
- Duke Cancer Institute - Durham
- Carolina BioOncology Institute - Huntersville
Texas
- Mary Crowley Cancer Research - Dallas
- NEXT Oncology- San Antonio - San Antonio
Florida
- Florida Cancer Specialists & Research Institute - Sarasota
Michigan
- University of Michigan - Ann Arbor
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06399757
The ClinicalTrials.gov registry entry for NCT06399757 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Apollo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which APL-5125 is the first listed.
NCT06399757 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06399757 about?
NCT06399757 is a clinical study titled "A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors". This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
What is the current status of trial NCT06399757?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-06-18. Estimated completion is 2027-05.
What conditions does trial NCT06399757 study?
This clinical trial studies the following conditions: Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06399757?
The interventions under investigation include: APL-5125 (DRUG).
Who is sponsoring clinical trial NCT06399757?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399757 being conducted?
This trial has 9 study locations across California, Florida, Michigan, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.